相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Journey Through Cholesteryl Ester Transfer Protein Inhibition From Bench to Bedside
Ioannis Karalis et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2013)
Mechanisms of Acute Coronary Syndromes and Their Implications for Therapy
Peter Libby
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Niacin Reduces Atherosclerosis Development in APOE*3Leiden.CETP Mice Mainly by Reducing NonHDL-Cholesterol
Susan Kuhnast et al.
PLOS ONE (2013)
Cholesterol Efflux and Atheroprotection Advancing the Concept of Reverse Cholesterol Transport
Robert S. Rosenson et al.
CIRCULATION (2012)
Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction
D. E. Gutstein et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
On- and Off-Target Pharmacology of Torcetrapib
Douglas G. Johns et al.
DRUGS (2012)
Aliskiren inhibits atherosclerosis development and improves plaque stability in APOEM*3Leiden.CETP transgenic mice with or without treatment with atorvastatin
Susan Kuhnast et al.
JOURNAL OF HYPERTENSION (2012)
Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib
Ronald M. Krauss et al.
JOURNAL OF LIPID RESEARCH (2012)
Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk
Philip J. Barter et al.
JOURNAL OF LIPID RESEARCH (2012)
Everyone under statin?
Helene Vaillant-Roussel et al.
EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE (2012)
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study
Benjamin F. Voight et al.
LANCET (2012)
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
Gregory G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
B. Mihaylova et al.
LANCET (2012)
Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL Cholesterol A Randomized Controlled Trial
Stephen J. Nicholls et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Cholesterol Efflux Potential and Antiinflammatory Properties of High-Density Lipoprotein After Treatment With Niacin or Anacetrapib
Laurent Yvan-Charvet et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
C. Baigent et al.
LANCET (2010)
Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease.
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients
Daniel Bloomfield et al.
AMERICAN HEART JOURNAL (2009)
Major Lipids, Apolipoproteins, and Risk of Vascular Disease
The Emerging Risk Factors Collaboration*
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Niacin Increases HDL by Reducing Hepatic Expression and Plasma Levels of Cholesteryl Ester Transfer Protein in APOE*3Leiden.CETP Mice
Jose W. A. van der Hoorn et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice
Willeke de Haan et al.
ATHEROSCLEROSIS (2008)
Cholesteryl Ester Transfer Protein Inhibitor Torcetrapib and Off-Target Toxicity A Pooled Analysis of the Rating Atherosclerotic Disease Change by Imaging With a New CETP Inhibitor (RADIANCE) Trials
Menno Vergeer et al.
CIRCULATION (2008)
Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin
Willeke de Haan et al.
CIRCULATION (2008)
Multiple-Dose Pharmacodynamics and Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Subjects
R. Krishna et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies
Rajesh Krishna et al.
LANCET (2007)
Effects of torcetrapib in patients at high risk for coronary events
Philip J. Barter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression
Caroline C. van der Hoogt et al.
JOURNAL OF LIPID RESEARCH (2007)
Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits
Lee A. Morehouse et al.
JOURNAL OF LIPID RESEARCH (2007)
Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE* 3-Leiden mice
Marit Westerterp et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway
F Matsuura et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
C Baigent et al.
LANCET (2005)
Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations
MH Davidson et al.
AMERICAN JOURNAL OF CARDIOLOGY (2005)
Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease
SM Boekholdt et al.
JOURNAL OF LIPID RESEARCH (2003)
Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia
ZP Huang et al.
CLINICAL SCIENCE (2002)
A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits
H Okamoto et al.
NATURE (2000)
Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis
CW Rittershaus et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2000)
分享论文
